Skip to main content
SLDB logo

SLDB · Solid Biosciences Inc.

Track SLDB — free
$6.25 -0.19 (-2.95%) At close · Nov 20
Market Cap
$697.57M
Shares
111.61M
Volume · Nov 20 1.56M Avg daily vol (3M) 1.29M

Price & Indicators

 

Key stats

Close
$6.25
Fri 20 Nov
Open
$6.34
Fri 20 Nov
Average volume, 30 days
1.4M
shares a session
Short interest
13.3M
11.9% of shares · 10.7 days to cover
Day range
$6.20$6.53
Open $6.34 Close $6.25
52-week closing range
$4.46$11.15
Close $6.25 43.9% under the high
Short volume, last session
71%
Last earnings
Feb 18, 2025
Latest filing
10-Q · Nov 4
Price history
Jan 2020 to Nov 2026

Up next

call held Apr 27, 2022

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SGT-003 Phase 3 dosing begins with runway into 2028

Solid dosed SGT-003 in Phase 3 IMPACT DUCHENNE in April 2026 and scheduled an FDA Type C meeting. Its $348.9 million in cash and securities is expected to fund operations into the first half of 2028.

Net loss $53.95M Diluted EPS -$0.36
Read from the MD&A section
5 source passages
Solid was purpose-built to advance the best science and accelerate the discovery and development of treatments that may benefit all patients with Duchenne. In October 2025, we activated the first clinical trial site and began screening participants for IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled trial evaluating SGT-003. Participant screening is underway and we dosed our first participant in the IMPACT DUCHENNE trial in April 2026. We have scheduled a Type C meeting with the FDA late in the fourth quarter of 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003; we expect to provide an update following the receipt of formal meeting minutes. As of September 30, 2026, we had cash, cash equivalents, and available-for-sale securities of $348.9 million, excluding restricted cash of $1.3 million. We believe that our cash, cash equivalents, and available-for-sale securities as of September 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2028. Open the document at this passage
Aug 6
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$215.27M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-28.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$125.97M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+60.0%
Year over year · more shares
Price change (1Y)
+40.1%
Trailing year
Short interest
11.9%
Latest settlement · 10.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −9%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 27%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +6%
trailing
6-month return −5%
trailing
YTD return +11%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.92% of shares out · ▲ +8.2% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
158 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Fair
Revenue growth −41%
Y/Y
EPS growth +35%
Y/Y
Free cash flow $-157.4M
Balance sheet $59.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 77%
annualized · 1-yr
Max drawdown −51%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
27% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.92% of shares out · ▲ +8.2% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
158 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $6 · 27% Range high $11
vs 200-day avg -19% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLDB
Solid Biosciences Inc.
this stock
$697.57M +10.8% -40.6% — 11.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
158
% held
106.5%
Net QoQ
+4.4M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
165
View
Short & Settlement
Short Interest Rising
Shares short
13.3M
Days to cover
10.7d
Change
+1.0M sh
View
Short Volume
Short vol %
71%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
126
Value
$805
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
40.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$8.1M
Net income (FY)
$-117.2M
EPS diluted
$-1.99
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
16

Solid dosed SGT-003 in Phase 3 IMPACT DUCHENNE in April 2026 and scheduled an FDA Type C meeting. Its $348.9 million in cash and securities is expected to fund operations into the first half of 2028.

View
Proposed Sales
Value
$32.4K
Shares
5.6K
Filed
Feb 18, 2026
View
Exempt Offerings
Offering
$9.2M
Filed
Dec 9, 2022
View
Earnings & Events
Webcasts
Last webcast
Feb 18, 2025
View
Investor Relations
Latest news
Solid Biosciences Reports Third Q…
Published
Nov 3, 2025
View

Performance

5D 20D 120D MTD YTD
SLDB -8.6% +5.6% -5.0% +0.8% +10.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -0.1% +14.8% +4.2% +9.5% +9.7%
Key facts CIK 1707502 CUSIP 83422E204 13F (30d) 160 filings 144 filers Visit website Investor relations